Vousoughi Gita, Soleimanzadeh Hamid, Radkhah Nima, Asghari Jafarabadi Mohammad, Bahri Fatemeh, Ostadrahimi Alireza, Ebrahimzadeh Attari Vahideh
Student Research Committee, Tabriz University of Medical Sciences Tabriz Iran.
Nutrition Research Center Tabriz University of Medical Sciences Tabriz Iran.
Food Sci Nutr. 2025 Aug 11;13(8):e70777. doi: 10.1002/fsn3.70777. eCollection 2025 Aug.
Kidney stones (nephrolithiasis) are a common and costly medical condition frequently linked with metabolic disorders. These disorders elevate the risk of serious complications and often necessitate invasive, expensive treatments, highlighting the need for alternative therapies. This study aimed to evaluate the effects of boron supplementation-in the form of boric acid and boron citrate-on kidney stone size and number in patients with nephrolithiasis. In this double-blind, randomized, placebo-controlled clinical trial, 60 eligible patients aged 20-65 years with nephrolithiasis were enrolled. Participants were randomly assigned to receive daily oral supplements for 8 weeks: boric acid (10 mg), boron citrate (10 mg), or placebo. The primary outcomes were kidney stone size and number; secondary outcomes included paraclinical parameters. Boron supplementation with either boric acid or boron citrate did not significantly reduce the number of kidney stones in fully adjusted models compared to the control group. The incidence rate ratios (IRR) were 1.09 (95% CI: 0.65-1.85; -value = 0.740) for boric acid and 1.30 (95% CI: 0.79-2.13; -value = 0.296) for boron citrate. Quade analysis also revealed no significant differences in kidney stone size among the groups. Regarding laboratory parameters, only urine phosphorus levels were significantly elevated in the boric acid group compared to placebo. No other clinically relevant effects were observed. Despite previous preliminary evidence, this study found no beneficial evidence for boron supplementation in patients with nephrolithiasis. IRCT20210914052469N1 (www.irct.behdasht.gov.ir).
肾结石（肾石病）是一种常见且代价高昂的病症，常与代谢紊乱相关。这些紊乱会增加严重并发症的风险，且往往需要进行侵入性、昂贵的治疗，凸显了替代疗法的必要性。本研究旨在评估以硼酸和柠檬酸硼形式补充硼对肾结石患者结石大小和数量的影响。在这项双盲、随机、安慰剂对照的临床试验中，纳入了60名年龄在20至65岁之间符合条件的肾结石患者。参与者被随机分配接受为期8周的每日口服补充剂：硼酸（10毫克）、柠檬酸硼（10毫克）或安慰剂。主要结局是肾结石的大小和数量；次要结局包括辅助临床参数。与对照组相比，在完全调整的模型中，补充硼酸或柠檬酸硼均未显著减少肾结石的数量。硼酸的发病率比（IRR）为1.09（95%CI：0.65 - 1.85；P值 = 0.740），柠檬酸硼的发病率比为1.30（95%CI：0.79 - 2.13；P值 = 0.296）。四格分析还显示各组间肾结石大小无显著差异。关于实验室参数，与安慰剂相比，仅硼酸组尿磷水平显著升高。未观察到其他临床相关效应。尽管有先前的初步证据，但本研究未发现补充硼对肾结石患者有有益证据。IRCT20210914052469N1（www.irct.behdasht.gov.ir）
